Supra-inguinal fascia iliaca nerve block for pain after hip replacement
Supra Inguinal Fascia Iliaca Block as Rescue Analgesia Following Total Hip Arthroplasty
This project will try a supra-inguinal fascia iliaca nerve block during primary total hip replacement to see if it reduces pain and the need for opioids afterward.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 310 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut Mutualiste Montsouris Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT06982625 on ClinicalTrials.gov |
What this trial studies
Adults scheduled for primary total hip arthroplasty under general anesthesia are randomized to receive either an ultrasound-guided supra-inguinal fascia iliaca block with ropivacaine or a placebo injection in addition to the standard surgical and anesthetic protocol. Pain scores, opioid consumption, and recovery milestones are recorded after surgery to compare groups. Rescue analgesia is available per protocol and perioperative care follows enhanced recovery principles. The trial focuses on whether adding this regional block improves early postoperative pain control and functional recovery.
Who should consider this trial
Good fit: Adults scheduled for a primary total hip arthroplasty under general anesthesia who can give written informed consent and have no contraindication to ropivacaine are eligible.
Not a fit: Patients who have surgical complications that prevent weight-bearing or walking, those without significant postoperative pain, or those allergic to local anesthetics are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, the block could lower postoperative pain and opioid requirements and speed early rehabilitation after hip replacement.
How similar studies have performed: Regional nerve blocks have reduced pain in other orthopedic procedures, and the supra-inguinal fascia iliaca block is a newer technique with encouraging but not yet definitive results for hip arthroplasty.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patient scheduled for a primary total hip arthroplasty under general anesthesia, * written informed consent. Non inclusion criteria: * contra indication to ropivacaine * vulnerable person Exclusion Criteria: * per-operative complication making wheight-bearing and walking contra-indicated. * patient without significant pain post-operatively.
Where this trial is running
Paris
- Institut Mutualiste Montsouris — Paris, France (Recruiting)
Study contacts
- Principal investigator: Abderrahmen BARGAOUI, MD — Institut Mutualiste Montsouris
- Study coordinator: Chahrazad Bey Boumezrag
- Email: chahrazad.beyboumezrag@imm.fr
- Phone: +33 156616983
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.